Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration

AstraZeneca today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin in Great Britain for the treatment of symptomatic chronic heart failure (HF) in patients with HF and a left ventricular ejection fraction (LVEF) >40%, including HF with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

China faces soaring Covid cases as hardline policy eases

Previous article

Dyson’s new air-purifying headphones come with a hefty price tag

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News